Alpha Teknova Reports 22% Revenue Growth in Q3 2026 Driven by Custom Product Demand
Alpha Teknova (TKNO) reported strong third-quarter 2026 financial results, highlighted by a 22% year-over-year increase in total revenue to $12.7 million. Growth was primarily fueled by the Clinical Solutions segment, which surged 86%, and increased demand for custom products within the life science tools and biopharma sectors. Gross margins also saw significant expansion, rising to 38.0% from 30.7% due to improved fixed cost absorption. Despite a net loss of $3.5 million, the company showed signs of operational improvement with an improved Adjusted EBITDA and reduced free cash outflow compared to the previous year. To strengthen its balance sheet, Alpha Teknova completed a $46 million equity raise in October 2026. Management has subsequently raised its full-year revenue guidance to a range of $46 million to $48 million, citing robust custom order volumes and a recovering biotech funding environment.
Tickers: $SPCX
Topics: equity raise financial guidance gross margin expansion revenue growth